Vimarsana
Biggest News Aggregation in the World

Page 14 - Allogeneic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Allogeneic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Allogeneic Today - Breaking & Trending Today

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting - Vimarsana News

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting

Presentations to feature clinical data from a Phase II CD30 CAR-T therapy study and a Phase I CD30 CAR-EBVST therapy study targeting lymphomasSINGAPORE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics

Takeda Pharmaceutical Company Limited: Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic ?dT Cell Therapies Addressing Solid Tumors - Vimarsana News

Takeda Pharmaceutical Company Limited: Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic ?dT Cell Therapies Addressing Solid Tumors

Acquisition expands Takeda's immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging gamma-delta T cells for the potential treatment of solid tumors and hematological

Waarschuwing voor "gedateerd" 'Allo Allo' door stereotype mo... - Vimarsana News

Waarschuwing voor "gedateerd" 'Allo Allo' door stereotype mo...

De legendarische tv-serie ‘Allo ‘Allo! krijgt in het Verenigd Koninkrijk voortaan een waarschuwing mee wanneer het uitgezonden of in een streamingkanaal aa...

GammaDelta Therapeutics Receives FDA Clearance of IND Application for GDX012, a Novel Allogeneic Variable Delta 1 Gamma-delta T Cell Cancer Therapy - Vimarsana News

GammaDelta Therapeutics Receives FDA Clearance of IND Application for GDX012, a Novel Allogeneic Variable Delta 1 Gamma-delta T Cell Cancer Therapy

First-in-human clinical study for Acute Myeloid Leukaemia expected to begin later in 2021 FDA also granted orphan drug designation to GDX012 for the treatment of Acute Myeloid Leukaemia GammaDelta

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, Off-the-Shelf Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma - Vimarsana News

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, Off-the-Shelf Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma

(0) Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021 BEDMINSTER, N.J. and SINGAPORE, May 14, 2021) testing TT11X in patients with CD30+ lymphomas. The results will be presented today at the 24 th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021). The presentation at ASGCT 2021 will highlight data from six patients treated with the therapy. The results demonstrated a favorable safety profile with encouraging clinical...